(Q36802594)

16 August 2017

1 reference

title

Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond (English)

1 reference

16 August 2017

Panagiotis A Konstantinopoulos

series ordinal

1

1 reference

16 August 2017

Michalis V Karamouzis

series ordinal

2

1 reference

16 August 2017

Athanasios G Papavassiliou

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

1 reference

16 August 2017

16

1 reference

16 August 2017

5

1 reference

16 August 2017

569-571

1 reference

Histone deacetylase inhibitors in cancer therapy

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Histone modifying enzymes and cancer: going beyond histones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

17-AAG: mechanisms of antitumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Histone deacetylase inhibitors in psoriasis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Theophylline in chronic obstructive pulmonary disease: new horizons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.569

10.1517/13543784.16.5.569

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference